JP2019510834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510834A5 JP2019510834A5 JP2019503794A JP2019503794A JP2019510834A5 JP 2019510834 A5 JP2019510834 A5 JP 2019510834A5 JP 2019503794 A JP2019503794 A JP 2019503794A JP 2019503794 A JP2019503794 A JP 2019503794A JP 2019510834 A5 JP2019510834 A5 JP 2019510834A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- pharmaceutically acceptable
- acid
- component
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- 102000009123 Fibrin Human genes 0.000 claims 4
- 108010073385 Fibrin Proteins 0.000 claims 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 230000008021 deposition Effects 0.000 claims 4
- 229950003499 fibrin Drugs 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000027032 Renal vascular disease Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606197.0 | 2016-04-08 | ||
| GB201606197 | 2016-04-08 | ||
| PCT/GB2017/051002 WO2017175013A1 (en) | 2016-04-08 | 2017-04-10 | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510834A JP2019510834A (ja) | 2019-04-18 |
| JP2019510834A5 true JP2019510834A5 (OSRAM) | 2020-05-21 |
| JP6985368B2 JP6985368B2 (ja) | 2021-12-22 |
Family
ID=58709491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503794A Active JP6985368B2 (ja) | 2016-04-08 | 2017-04-10 | バルプロ酸を含む遅延放出性薬学的製剤、及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11395808B2 (OSRAM) |
| EP (1) | EP3439649B1 (OSRAM) |
| JP (1) | JP6985368B2 (OSRAM) |
| KR (1) | KR102438395B1 (OSRAM) |
| CN (2) | CN109414423A (OSRAM) |
| AU (1) | AU2017246697B2 (OSRAM) |
| CA (1) | CA3018043A1 (OSRAM) |
| ES (1) | ES2969021T3 (OSRAM) |
| HU (1) | HUE064701T2 (OSRAM) |
| IL (1) | IL262163B2 (OSRAM) |
| MX (1) | MX395521B (OSRAM) |
| PL (1) | PL3439649T3 (OSRAM) |
| RU (1) | RU2760304C2 (OSRAM) |
| WO (1) | WO2017175013A1 (OSRAM) |
| ZA (1) | ZA201806766B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| PL3439649T3 (pl) | 2016-04-08 | 2024-03-18 | Cereno Scientific Ab | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
| CN113995742B (zh) * | 2021-10-22 | 2023-12-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 包含丙戊酸的美白组合物及其用途 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0300111B1 (en) | 1987-07-22 | 1991-10-16 | Farvalsa AG | A moisture stable solid valproic acid formulation and a method of preparing the same |
| WO2001022940A1 (en) * | 1999-09-30 | 2001-04-05 | Edward Mendell Co., Inc. | Sustained release matrix systems for highly soluble drugs |
| AT408718B (de) * | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20050276848A1 (en) | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| AU2006287378A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
| PL1937650T3 (pl) | 2005-09-08 | 2011-11-30 | Mei Pharma Inc | Związki heterocykliczne |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| DE602006003848D1 (de) * | 2006-01-11 | 2009-01-08 | Teva Pharma | Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| AU2007234380A1 (en) | 2006-04-06 | 2007-10-11 | Novartis Ag | Combination of organic compounds |
| KR101468053B1 (ko) * | 2006-08-31 | 2014-12-02 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템 |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| CN101947209B (zh) * | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| US20140051716A1 (en) * | 2011-03-09 | 2014-02-20 | Cereno Scientific Ab | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
| KR101892788B1 (ko) | 2011-09-13 | 2018-08-28 | 파마싸이클릭스 엘엘씨 | 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도 |
| CN104248627A (zh) * | 2013-06-25 | 2014-12-31 | 北大方正集团有限公司 | 丙戊酸半钠泡腾干混悬剂及其制备方法 |
| GB201417828D0 (en) * | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| US20200179381A1 (en) | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| PL3439649T3 (pl) | 2016-04-08 | 2024-03-18 | Cereno Scientific Ab | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
-
2017
- 2017-04-10 PL PL17723734.4T patent/PL3439649T3/pl unknown
- 2017-04-10 CN CN201780025746.XA patent/CN109414423A/zh active Pending
- 2017-04-10 AU AU2017246697A patent/AU2017246697B2/en active Active
- 2017-04-10 CA CA3018043A patent/CA3018043A1/en active Pending
- 2017-04-10 MX MX2018012224A patent/MX395521B/es unknown
- 2017-04-10 US US16/090,664 patent/US11395808B2/en active Active
- 2017-04-10 CN CN202111575415.8A patent/CN114209667A/zh active Pending
- 2017-04-10 ES ES17723734T patent/ES2969021T3/es active Active
- 2017-04-10 JP JP2019503794A patent/JP6985368B2/ja active Active
- 2017-04-10 WO PCT/GB2017/051002 patent/WO2017175013A1/en not_active Ceased
- 2017-04-10 HU HUE17723734A patent/HUE064701T2/hu unknown
- 2017-04-10 KR KR1020187031904A patent/KR102438395B1/ko active Active
- 2017-04-10 RU RU2018137399A patent/RU2760304C2/ru active
- 2017-04-10 EP EP17723734.4A patent/EP3439649B1/en active Active
-
2018
- 2018-10-07 IL IL262163A patent/IL262163B2/en unknown
- 2018-10-11 ZA ZA2018/06766A patent/ZA201806766B/en unknown
-
2022
- 2022-07-19 US US17/868,323 patent/US12023311B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017114933A (ru) | Соединения и композиции для лечения или профилактики патологических состояний, связанных с избыточным отложением фибрина и/или образованием тромбов | |
| JP6778680B2 (ja) | 錠剤 | |
| FI92904C (fi) | Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi | |
| JP2015057436A5 (OSRAM) | ||
| JP2019510834A5 (OSRAM) | ||
| JP2016528302A5 (OSRAM) | ||
| JP2014515373A5 (OSRAM) | ||
| JP2015512406A5 (OSRAM) | ||
| JP2017528507A5 (OSRAM) | ||
| JP2014533656A5 (OSRAM) | ||
| JP2017222722A5 (OSRAM) | ||
| JP2020523335A5 (OSRAM) | ||
| JP2015508068A5 (OSRAM) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| JP2017533211A5 (OSRAM) | ||
| RU2018137399A (ru) | Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение | |
| TW201202255A (en) | Novel composition for the prevention and/or treatment of thromboembolism | |
| DK164638B (da) | Kombinationspraeparat af pyrimido-pyrimidiner og acetylsalicylsyre og/eller deres farmaceutisk acceptable salte, fremgangsmaade til dets fremstilling samt anvendelse af pyrimido-pyrimidiner og acetylsalicylsyre og/eller salte deraf sammen med farmaceutiske baerere til fremstilling af et kombinationspraeparat | |
| FI3713576T3 (fi) | Yhdiste kaavan (i) mukaan ja ponatinibi käytettäväksi bcr-abl-mutaatioiden kanssa esiintyvän kroonisen myelooisen leukemian hoidossa | |
| JP2021503448A5 (OSRAM) | ||
| JP2008543853A (ja) | プラスグレルのための薬剤投与計画 | |
| NZ746269B2 (en) | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof | |
| WO2018113080A1 (zh) | 小檗碱的医药用途 | |
| JPWO2020099926A5 (OSRAM) |